<DOC>
	<DOCNO>NCT00185575</DOCNO>
	<brief_summary>The purpose study test hypothesis duloxetine ( Cymbalta ) , dose 60 120 mg/day , effective tolerable treatment adult outpatient suffer dysthymia . Dysthymia chronic , mild depression characterize feel sad low day 2 year .</brief_summary>
	<brief_title>Duloxetine Treatment Dysthymia</brief_title>
	<detailed_description>The purpose research obtain information safety effectiveness duloxetine ( Cymbalta ) treatment dysthymia . Duloxetine approve federal Food Drug Administration treatment depression . The use duloxetine treatment dysthymia consider experimental . Dysthymia define chronic , low-grade depression , characterize feeling low depress , last two year . Additional symptom may include : poor appetite overeating ; insomnia sleep much ; low energy fatigue ; low self-esteem ; poor concentration difficulty make decision ; feeling hopelessness . Dysthymia affect 3-6 % general population , underdiagnosed undertreated disorder . In double-blind , placebo-controlled clinical trial antidepressant medication , dysthymia response rate around 60 % , compare average placebo response rate 30 % . Duloxetine study treatment dysthymia , show result treatment major depression . In 9-week , double-blind , placebo-controlled study 257 patient major depression , 65 % respond duloxetine 60mg/day , compare 43 % placebo . Based result , highly likely duloxetine effective treatment dysthymia . This research study conduct Stanford University Medical Center total 24 patient , age 18 , dysthymia . In study , subject receive duloxetine 12 week . This open-label study , mean every subject receive study medication . In total , subject see 10 visit across 13 week . At visit subject ' heart rate , blood pressure weight measurement obtain . At visit study personnel interview subject symptom , monitor side effect ask complete study questionnaire . Beginning second visit , subject receive duloxetine 60 mg/day . If experience side effect , dose decrease 30 mg/day several day , increase back 60 mg/day end first week . If subject unable tolerate dose 60 mg/day due side effect , withdrawn study . At end 6 week , respond study medication ( determined doctor rating base subject ' report ) , dose duloxetine increase 120 mg/day , unless subject experience troubling side effect . Subjects continue minimum dose brings remission maximum tolerate dose remain 6 week . Medication dose flexible determine tolerance ( side effect ) therapeutic effect .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>: Sign informed consent form 18 year age old Females pregnant breastfeeding planning pregnancy use acceptable form contraception Meet DSMIV criterion dysthymia A screening IDSC score 17 great No history serious unstable medical disorder Not take significant concurrent medication Not currently receive psychotherapy Suffering DSMIV define delirium , dementia , amnestic , cognitive disorder mental disorder due general medical condition factitious somatoform disorder mental retardation developmental disability substance alcohol abuse within last 3 month depressive disorder current suicidal risk psychotic disorder include delusional disorder , somatic type dissociative disorder personality disorder sufficiently severe interfere study participation History DSMIV define bipolar I II disorder History nonresponse dysthymia adequate antidepressant medication History major depression refractory two adequate trial antidepressant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>